Lactobacillus Gasseri for Belly Fat: Does SBT2055 Work?

Of all the probiotics marketed for "belly fat," Lactobacillus gasseri SBT2055 is the one with an actual headline number behind it: a roughly 8–9% drop in visceral fat over 12 weeks in a randomized trial. That sounds like the holy grail of supplements — a pill that targets the dangerous fat around your organs. The result is real, and it's worth understanding. But two caveats turn it from a miracle into a modest, conditional tool: the effect appears to depend on a specific strain at a continuous dose, and when people stopped taking it, the fat came back. This page sticks to what the controlled human trials actually showed.

The trial that started it all

The famous result comes from a 2010 randomized controlled trial by Kadooka and colleagues. They gave 87 Japanese adults with "obese tendencies" (elevated BMI and abdominal fat) fermented milk containing L. gasseri SBT2055, or the same milk without the strain, for 12 weeks. The probiotic group saw visceral fat area fall by about 4.6% and subcutaneous fat by about 3.3%, while body weight, BMI, and waist circumference also dropped significantly versus the control group ¹. Different write-ups quote slightly different "belly fat" percentages because the trial measured several fat compartments; the commonly cited "~8–9%" figures come from the larger reductions seen in specific measures and in the follow-up study below.

The single most important detail in that paper is what happened after the trial. During a 4-week follow-up with no probiotic, the abdominal fat reductions reversed — the fat began returning toward baseline once the daily dose stopped ¹. That is the honest headline: this is not a one-time reset. Any benefit is contingent on continued daily intake, much like a medication you'd have to keep taking.

A second trial confirmed it — at a lower dose, and with the same catch

A 2013 follow-up by the same group tested whether a smaller daily dose still worked. In 210 adults over 12 weeks, fermented milk with SBT2055 again significantly reduced visceral fat area (roughly 8–9% from baseline in the active groups) along with waist and hip circumference, compared with control ². This replication matters — a single trial is easy to dismiss, two independent trials from a controlled program are harder to wave away. But this study, too, only measured the on-treatment window; nothing here suggests the effect outlasts the dosing.

So the human evidence for SBT2055 specifically is genuinely better than for most "metabolic" probiotics: two randomized trials, real anthropometric and imaging endpoints, consistent direction. That earns it a moderate evidence grade — better than the generic-probiotic average, but still short of a durable, drug-like treatment.

How it might work — and how much is still animal data

It's worth being clear about where the mechanism evidence is human versus rodent. In a human study, SBT2055 increased fecal fat excretion and appeared to enlarge fat-emulsion droplets in vitro, suggesting it reduces how much dietary fat the gut absorbs ³ — a plausible, partly-human mechanism for fat loss. The rest of the mechanistic story, though, is largely from mice: in diet-induced obese mice, SBT2055 suppressed macrophage infiltration into adipose tissue ⁴ and reduced adipose-tissue inflammation and intestinal permeability ("leaky gut") on a high-fat diet ⁵. In a diabetic rat model it improved insulin secretion ⁶. These are encouraging and biologically coherent, but animal metabolic findings frequently fail to translate cleanly to humans — so treat the anti-inflammatory and insulin angles as mechanism, not proven human benefit. (For why intestinal permeability matters metabolically, see leaky gut and metabolism, and for the broader insulin story, the microbiome and insulin resistance.)

The strain-specificity trap

Here's where marketing gets ahead of the science. The trials were done with one strain — SBT2055 — in a fermented-milk matrix. Probiotic effects are notoriously strain-specific: a result for L. gasseri SBT2055 does not transfer to "Lactobacillus gasseri" as a category, let alone to a generic "weight-loss probiotic" blend on a shelf. If a product simply lists "L. gasseri" without the SBT2055 designation (and a dose in the range the trials used), you are not buying the thing that was studied. This is the same trap we flag across the category: the meta-analysis of probiotics for weight finds only a small average effect of about −0.6 kg, precisely because it pools many different strains and products, most of which weren't SBT2055 ⁷. We unpack that pooled picture in do probiotics help weight and metabolism?.

Safety and honest expectations

For most healthy people, L. gasseri is well tolerated. The general probiotic-safety caveat still applies: documented risks of bloodstream infection exist in immunocompromised or critically ill patients, plus product-quality concerns, so anyone with a serious medical condition should check with a clinician first ⁸. Beyond safety, the realistic framing is this: even in the best case, SBT2055 produced a modest reduction in visceral fat that reversed on stopping — useful as one lever within a fiber-rich, whole-food pattern, not a replacement for it and nowhere near what GLP-1 medications achieve. If you're choosing among marketed products, our evidence-tiered best probiotics for weight loss rundown and our best metabolic probiotic hub keep this same strain-specific honesty, and the mechanism that actually moves metabolism most — fermentable fiber feeding your own GLP-1 — is covered in our pillar on the gut–metabolism connection.

The honest bottom line

L. gasseri SBT2055 is one of the few probiotics with real randomized-trial evidence for reducing visceral ("belly") fat — about an 8–9% reduction over 12 weeks across two trials. But the effect is strain-specific, dose-dependent, modest in absolute terms, and — critically — it reversed within weeks of stopping. Buy the studied strain or don't bother; and treat it as a continuous, supporting tool, not a cure for abdominal fat.